Transcription factors NRF2 and NF-κB are coordinated effectors of the Rho family, GTP-binding protein RAC1 during inflammation by Cuadrado, Antonio et al.
Transcription Factors NRF2 and NF-B Are Coordinated
Effectors of the Rho Family, GTP-binding Protein RAC1 during
Inflammation*
Received for publication,December 6, 2013, and in revised form, April 21, 2014 Published, JBC Papers in Press, April 23, 2014, DOI 10.1074/jbc.M113.540633
Antonio Cuadrado‡, Zaira Martín-Moldes‡§, Jianping Ye¶, and Isabel Lastres-Becker‡1
From the ‡Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de
Investigación Sanitaria La Paz (IdiPAZ), Departamento de Bioquímica e Instituto de Investigaciones Biomédicas “Alberto Sols”
CSIC-UAM, Facultad deMedicina, Universidad Autónoma deMadrid, 28029Madrid, Spain, §Department of Environmental
Biology, Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas, 28040Madrid, Spain, and
¶Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, Louisianna 70808
Background: RAC1 is a small G-protein of the Rho family that activates the transcription factor NF-B to elicit an inflam-
matory response.
Results: We have found that RAC1 also induces the NRF2/ARE pathway, which in term blocks RAC1-dependent NF-B
activation.
Conclusion: RAC1 modulates inflammation by coordinating the activity of pro-inflammatory NF-B and anti-oxidant NRF2
transcription factors.
Significance: Therapeutic intervention on RAC1 could help modulate pro- and anti-inflammatory processes.
The smallGTPase proteinRAC1participates in innate immu-
nity by activating a complex program that includes cytoskeleton
remodeling, chemotaxis, activation of NADPH oxidase, and
modulation of gene expression. However, its role in regulating
the transcriptional signatures that in term control the cellular
inflammatory profiles are notwell defined.Herewe investigated
the functional and mechanistic connection between RAC1 and
the transcription factor NRF2 (nuclear factor erythroid 2-re-
lated factor 2), master regulator of the anti-oxidant response.
Lipopolysaccharide and constitutively active RAC1Q61L mutant
induced the anti-oxidant enzyme heme-oxygenase-1 (HO-1)
through activation of NRF2. The use of KEAP1-insensitive NRF2
mutants indicated that RAC1 regulation of NRF2 is KEAP1-
independent. Interestingly, NRF2 overexpression inhibited,
whereas a dominant-negative mutant of NRF2 exacerbated
RAC1-dependent activation of nuclear factor-B (NF-B), sug-
gesting that NRF2 has an antagonistic effect on theNF-B path-
way. Moreover, we found that RAC1 acts through NF-B to
induce NRF2 because either expression of a dominant negative
mutant of IB that leads to NF-B degradation or the use of
p65-NF-B-deficient cells demonstrated lower NRF2 protein
levels and basally impairedNRF2 signature compared with con-
trol cells. In contrast, NRF2-deficient cells showed increased
p65-NF-B protein levels, although the mRNA levels remain
unchanged, indicating post-translational alterations. Our
results demonstrate a new mechanism of modulation of RAC1
inflammatory pathway through a cross-talk betweenNF-B and
NRF2.
The Rho GTPase RAC1 is a pleiotropic regulator of many
cellular processes. It is a well established that RAC1 is a medi-
ator in execution of the inflammatory program of the innate
immune system (1–3). Among several roles assigned to RAC1
in inflammation, its participation in cytoskeleton remodeling
and chemotaxis as well as in NADPH oxidase-dependent pro-
duction of superoxide have been well established (4, 5). More-
over, RAC1 leads to activation of the transcription factor
NF-B and its target genes, including several proinflammatory
cytokines such asTNF (4, 6). However, it is not knownhow cells
activated by RAC1 ultimately change their gene expression
back to a “resting” state or toward a resolution profile.
One of the pathways implicated in the control of inflamma-
tion is the transcription factor nuclear factor (erythroid-de-
rived 2)-like 2 (NRF2),2 which is a master regulator of redox
homeostasis (7). NRF2 regulates the expression of a battery of
cytoprotective genes that share in common a cis-acting
enhancer sequence termed antioxidant response element
(ARE) (8, 9). These genes include those coding the antioxidant
enzymes heme oxygenase-1 (HO-1) and NADP(H) quinone
oxidoreductase (NQO1), enzymes of glutathione metabolism
and protein degradation, through the proteasome and auto-
phagy routes (10, 11). Previous data from our group indicated
that NRF2 knock-out mice are hypersensitive to the inflamma-
tion induced by LPS (12) and exhibit exacerbated activation of
the brain resident macrophage, microglia, in comparison to
their wild type littermates. Interestingly, the treatment with
sulforaphane, a compound that induces NRF2-dependent gene
expression, attenuated the LPS-induced microglial infiltration
* This work was supported by Spanish Ministerio de Ciencia e Innovacion
Grant SAF2010-17822.
1 Recipient of a Ramón y Cajal contract (Ministerio de Ciencia e Innovacion-
RYC and to whom correspondence should be addressed: Instituto de
Investigaciones Biomédicas “Alberto Sols” UAM-CSIC, c/ ArturoDuperier 4,
28029 Madrid, Spain. Tel.: 34-915854383; Fax: 34-915854401; E-mail:
ilbecker@iib.uam.es.
2 Theabbreviationsusedare:NRF2, nuclear factor erythroid2-related factor 2;
ARE, antioxidant response element; HO-1, heme oxygenase-1; SFN,
sulforaphane; SOD, superoxide dismutase; DN, dominant-negative; ROS,
reactive oxygen species; MEF, mouse embryo fibroblast; XIAP, X-chromo-
some-linked inhibitor of apoptosis; qRT, quantitative real-time; Keap1,
Kelch-like ECH-associated protein 1.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 289, NO. 22, pp. 15244–15258, May 30, 2014
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.
15244 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 289•NUMBER 22•MAY 30, 2014
 at CSIC - Centro de Investigaciones Biológicas on Septem
ber 6, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
to the hippocampus, reinforcing the idea of NRF2 anti-inflam-
matory properties. This evidence has been corroborated in
other recent reports by analyzing other cells of the monocyte-
macrophage linage (8, 13–15). On the other hand, the tran-
scription factor nuclear factor B (NF-B) plays a crucial role in
immune responses through the regulation of genes encoding
proinflammatory cytokines, adhesion molecules, chemokines,
growth factors, and inducible enzymes (16). It is remarkable
that NRF2 and NF-B influence each other and coordinate the
final fate of innate immune cells (17), but it is not known how
this interconnection takes place.
In this study we report that RAC1 induces the anti-inflam-
matory NRF2/HO-1 pathway. We also provide evidence that
NF-B activity is induced by active RAC1 and that NRF2 can
modulate this effect. These results uncover a new mechanism
of regulation of inflammatory events trough a RAC1/NRF2/
HO-1 axis.
EXPERIMENTAL PROCEDURES
Cell Culture and Reagents—Human embryonic kidney (HEK)
293T cells were grown in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum and 80
g/ml gentamycin. Transient transfections were performed
with calcium phosphate using reagents from Sigma. BV-2
microglial cells were cultured in RPMI 1640 medium supple-
mented with 10% FCS and 80 g/ml gentamicin. Cells were
changed to serum-free RPMI without antibiotics 16 h before
the addition of LPS (Sigma). HEK-TLR4-MD2/CD14 cells were
kindly provided by Dr. Manuel Fresno (Centro de Biología
Molecular Severo Ochoa (CBMSO), Madrid, Spain). These
cells were grown inDMEMcontaining 4.5 g/liter glucose, 4mM
L-glutamine, 10% fetal bovine serum, 50 units/ml penicillin, 50
g/ml streptomycin, 10g/ml blasticidin and 50g/mlHygro-
gold. The p65/ mouse embryo fibroblasts (MEFs) and their
corresponding wild type p65/MEFswere kindly provided by
Dr. Jianping Ye (Pennington Biomedical Research Center, Lou-
isiana State University, Baton Rouge, LA) (18). The NRF2/
and NRF2/ MEFs were isolated around embryonal day 17.
Skin pieces were minced in 3-cm Petri dishes and underwent
enzymatic digestion at 37 °C for 30 min in Falcon tubes with 1
ml of HyQTase (Hyclone). The digested tissue was passed
through a 160-m Nitex filter into 3-cm Petri dishes, and the
enzymes were neutralized with DMEM plus 15% FCS (Sigma).
The resulting suspension was centrifuged at 450 g for 5 min,
and the cells were plated at a density of 1  106 cells/cm2 in
culture flasks. The fibroblasts were placed in an incubator at
37 °C supplemented with 5% CO2, and medium was changed
daily for the first 3 days. After near confluence, cells were
detached with HyQTase and replated at a density of 1  106
cells/cm2 in 6-cm plates every third day. MEFs were grown in
DMEM supplementedwith 10% fetal bovine serum, 1% penicil-
lin/streptomycin, and 2 mM L-glutamine. Sulforaphane (SFN)
(LKT Laboratories, St. Paul, MN) was used at 14 M for 6 h.
GST Pulldown Assays—The RAC1 binding domain from
GST fusion of the PAK1 p21 binding domain (19) was
expressed in Escherichia coli as a fusion protein with glutathi-
one S-transferase. BV-2 were treated for different times with
LPS (500 ng/ml) and then lysed in a buffer composed of 50 mM
Tris-HCl, pH 7.5, 1% Triton X-100, 100 mM NaCl, 10 mM
MgCl2, 5% glycerol, 1 mM Na3VO4, and protease inhibitors (20
g/ml aprotinin; pepstatin and leupeptin (1 g/ml each).
Lysates were centrifuged at 15,000  g for 10 min, and the
Triton X-100-soluble fraction was recovered. A bacterial lysate
containing the GST-PAK1 fusion protein was added to BV-2
lysates together with glutathione-Sepharose beads. After 1 h
the beads were collected by centrifugation and washed 3 times
in 25 mM Tris-HCl, pH 7.5, 1% Triton X-100, 1 mM dithiothre-
itol, 100 mM NaCl, and 30 mM MgCl2. The beads were then
resuspended in Laemmli sample buffer and boiled under reduc-
ing conditions for 5 min. The precipitated proteins were sub-
jected to 12% SDS-PAGE and transferred to PVDFmembranes.
The membranes were blocked in TBS supplemented with 0.2%
Tween 20 and 5% milk and then incubated for 1 h with a pri-
mary antibody (anti-RAC1) and thereafter washed 3 times for 5
min in TBS supplemented with 0.2% Tween 20. The mem-
branes were subsequently incubated for 1 h with peroxidase-
conjugated anti-mouse IgGs (1:10,000) in TBS supplemented
with 0.2% Tween 20. The blots were extensively washed, and
antibody binding was visualized by enhanced chemilumines-
cence. In another set of experiments we confirmed RAC1 acti-
vation with anti-active GTP-RAC1 antibody (#26903, NewEast
Biosciences).
Plasmids—Expression vectors pcDNA3.1/V5HisB-mNRF2
and pcDNA3.1/V5HisB-mNRF2ETGE are described in Mc-
Mahon et al. (20). For luciferase assays, transient transfections of
HEK293T cells were performed with the expression vectors
pHO1–15-LUC, ARE-LUC, pEF-NRF2(DN), and ARE-mut-
LUC (Dr. J. Alam, Dept. of Molecular Genetics, Ochsner Clinic
Foundation, New Orleans, LA). pcDNA3-IBS32A/S36A was
described in Traenckner et al. (21), and pCEFL-AU5-
RAC1Q61Lwas kindly provided byDr. Silvio Gutkind, NIDCR,
National Institutes of Health, Bethesda, MD. pCCMV-p65,
pCCMV-p50, and NF-B-dependent (453/80)-HIV-LUC
are described in Rojo et al. (22). pcDNA3-Gal4-NRF2 was gen-
erated in our laboratory and described in Espada et al. (23).
LuciferaseAssays—Transient transfections ofHEK293T cells
were performed with the expression vectors for TK-Renilla
(Promega, Madison, CA) and the corresponding firefly lucifer-
ase reporters. Cells were seeded on 24-well plates (100,000 cells
perwell), cultured for 16 h, and transfected using calciumphos-
phate. After 24 h of recovery from transfection, the cells were
lysed and assayedwith a dual-luciferase assay system (Promega)
according to the manufacturer’s instructions. Relative light
units were measured in a GloMax 96 microplate luminometer
with dual injectors (Promega).
Immunoblotting—Cells were washed once with cold PBS and
lysed on ice with radioimmune precipitation assay lysis buffer
(150 mM NaCl, 25 mM Tris-HCl, pH 7.5, 1% Nonidet P-40, 1%
sodium deoxycholate, 0.1% SDS, 1 mM phenylmethylsulfonyl
fluoride, 1mMNaF, 1mM sodiumpyrophosphate, 1mM sodium
orthovanadate, 1 g/ml leupeptin, 1 mm EGTA). Precleared
cell lysates were resolved in SDS-PAGE and transferred to
Immobilon-P membranes (Millipore, Billerica, MA). The pri-
mary antibodies used were anti-V5 (Invitrogen), anti-GAPDH
(Merck), anti-NF-B (p65, RelA) (Calbiochem,Merck), anti--
actin (sc-1616) and anti-laminB (sc-6217) (SantaCruzBiotech-
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nology), anti-HO-1 (AB1284, Millipore), anti-AU5 (Covance,
Berkeley, CA), anti-IBA1 (ab5076, Abcam, Cambridge, UK),
anti-NRF2 (1:1000, Abyntek, Spain), anti-MnSOD (Stressgen),
and anti-XIAP (Sigma). Thesemembranes were analyzed using
the primary antibodies indicated above and the appropriate
peroxidase-conjugated secondary antibodies. Proteins were
detected by enhanced chemiluminescence (GE Healthcare).
Preparation of Nuclear and Cytosolic Extracts—HEK293T
and HEK-TLR4-MD2/CD14 cells were seeded in p100 plates
(2 106 cells/plate) and transfected with calcium phosphate or
treated with 1 mg/ml LPS, respectively. Cytosolic and nuclear
fractions were prepared as described previously (22). Briefly,
cells were washed with cold PBS and harvested by centrifuga-
tion at 1100 rpm for 10 min. The cell pellet was resuspended in
3 pellet volumes of cold buffer A (20 mM HEPES, pH 7.0, 0.15
mM EDTA, 0.015 mM EGTA, 10 mM KCl, 1% Nonidet P-40, 1
mM phenylmethylsulfonyl fluoride, 20 mM NaF, 1 mm sodium
pyrophosphate, 1 mM sodium orthovanadate, 1 g/ml leupep-
tin) and incubated in ice for 30 min. Then the homogenate was
centrifuged at 500 g for 5 min. The supernatants were taken
as the cytosolic fraction. The nuclear pellet was resuspended in
5 volumes of cold buffer B (10 mM HEPES, pH 8.0, 0.1 mM
EDTA, 0.1 mMNaCl, 25% glycerol, 1 mM phenylmethylsulfonyl
fluoride, 20 mM NaF, 1 mM sodium pyrophosphate, 1 mM
sodium orthovanadate, 1 g/ml leupeptin). After centrifuga-
tion in the same conditions indicated above, the nuclei were
resuspended in loading buffer containing 0.5% SDS. The cyto-
solic and nuclear fractions were resolved in SDS-PAGE and
immunoblotted with the indicated antibodies.
Analysis of mRNA Levels by Quantitative Real-time PCR—
Total RNA from microglial primary cultures and from BV-2
cells was extracted using TRIzol reagent according to the man-
ufacturer’s instructions (Invitrogen). One microgram of RNA
from each experimental condition was treated with DNase
(Invitrogen) and reverse-transcribed using 4 l of High capac-
ity RNA-to-cDNA Master Mix (Applied Biosystems, Foster
City, CA). For real-time PCR analysis, we performed the
method previously described by Rojo et al. (13). Primer
sequences are shown in Table 1. To ensure that equal amounts
of cDNA were added to the PCR, the -actin housekeeping
gene was amplified. Data analysis is based on theCtmethod
with normalization of the raw data to housekeeping genes as
described in the manufacturer’s manual (Applied Biosystems,
Invitrogen). All PCRs were performed in triplicate.
Reactive Oxygen Species (ROS) Production—The fluorescent
probe 2-7-dihydrodichlorofluorescein diacetate was used to
assess ROS production (24). Cells were transfected, and after 24 h
of recovery from transfection, the cells were incubatedwith 2-7-
dihydrodichlorofluorescein diacetate 100 mM for 1 h. Fluores-
cence intensity was measured in a Synergy fluorescence micro-
plate reader (Bio-Tek Instruments, Inc.,Winooski, VT).
Electrophoretic Mobility Shift Assays—The double-stranded
oligonucleotide used for the NF-B probe was 5-AGTT-
GAGGGACTTTCCCAGGC-3 (25) and for Nrf2 probe was
5-TTTTATGCTGTGTCATGGTT-3 (26). Then 250 ng/l
concentrations of each oligonucleotide was annealed by incu-
bation in STE buffer (100 mM NaCl, 10 mM Tris-HCl, pH 8.0,
and 1 mM EDTA) at 80 °C for 2 min. The mixture was cooled
down slowly to 4 °C, with a thermal profile of 1 °C/min.
Annealed oligonucleotides were diluted to 25 ng/l in STE
buffer. 5-End labeling was performed with T4 polynucleotide
kinase (Promega) using 25 ng of double-stranded oligonucleo-
tide and 25Ci of [-32P]ATP (3000 Ci/mmol; AmershamBio-
sciences). The labeled probes were purified in a G-25 spin col-
umn (Amersham Biosciences). The binding reaction mixture
contained 5 g of nuclear protein extract diluted in a buffer
containing, at final concentration, 40 mM HEPES, pH 8.0, 50
mM KCl, 0.05% Nonidet P-40, 1% dithiothreitol, and 10 g/ml
poly(dI-dC) in a total volume of 20 l. Unlabeled competitor
probe (25 ng) was added, and the reaction was incubated for 1 h
at 25 °C. Labeled DNA (0.25 ng) was added to the mixture and
was submitted to an additional 20 min incubation at 25 °C.
Samples were resolved at 4 °C in a 6% non-denaturing poly-
acrylamide gel in 0.5 Tris borate/EDTA buffer. After electro-
phoresis the gel was dried and autoradiographed.
Statistical Analyses—Data are presented as the mean  S.E.
One and two-way analysis of variance with post hoc Newman-
Keuls test and Bonferroni’s test were used as appropriate.
Student’s t test was used to assess differences between groups.
The Prism Version 5.03 software forWindows (GraphPad, San
Diego, CA) was used as described in each figure legend.
RESULTS
LPS Activates RAC1 and Induces HO-1 in BV-2 Microglial
Cells—RAC1 activity was analyzed in cell lysates of BV-2 cells
treated with LPS in aGST pulldown assay. This assay was based
on the use of a chimeric protein made of glutathione S-trans-
ferase fused to the RAC1 interactive binding domain of p21-
TABLE 1
Genes and primers for quantitative PCR amplification
Genes and primers used for quantitative RT-PCR amplification. NQO1, NADP(H) quinone oxidoreductase; Gstm3, glutathione S-transferase M3; Gpx, glutathione
peroxidase.
Gene product Forward primer Reverse primer
Gpx 5-GGACTACACCGAGATGAACG-3 5-GATGTACTTGGGGTCGGTCA-3
Gstm3 5-GAGAAGCAGAAGCCAGAGT-3 5-ATACGATACTGGTCAAGAAT-3
Ho-1 5-CACAGATGGCGTCACTTCGTC-3 5-GTGAGGACCCACTGGAGGAG-3
IL-1 5-CTGGTGTGTGACGTTCCCATTA-3 5-CCGACAGCACGAGGCTTT-3
Mn-SOD 5-AACAATCTCAACGCCACCGA-3 5-GATTAGAGCAGGCAGCAATC-3
NRF2 5-CCCGAAGCACGCTGAAGGCA-3 5-CCAGGCGGTGGGTCTCCGTA-3
NQO1 5-GGTAGCGGCTCCATGTACTC-3 5-CATCCTTCCAGGATCTGCAT-3
p65 5-GGCCTCATCCACATGAACTT-3 5-CACTGTCACCTGGAAGCAGA-3
TNF 5-CATCTTCTCAAAATTCGAGTGACAA-3 5-TGGGAGTAGACAAGGTACAACCC-3
-Actin 5-TCCTTCCTGGGCATGGAG-3 5-AGGAGGAGCAATGATCTTGATCTT-3
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FIGURE 1. LPS activates RAC1 and increases HO-1 protein levels inmicroglia. A, BV-2 cells were treated with LPS (500 ng/ml) for 5, 10, 20, and 40min,
and cell lysates were used to perform a GST-PAK1-PBD pulldown assay as described under “Experimental Procedures.” As a negative control we used the
same cell lysate from 40 min of treatment but with a GST empty vector. Immunoblots with anti-RAC1 antibody: upper panel, active RAC1; lower panel,
total RAC1. B, quantification of immunoblots from two independent experiments for active RAC1 and total RAC1. One-way ANOVA followed by
Newman-Keuls test was used to assess differences among groups. Asterisks denote significant differences. ***, p 0.001, comparing the basal group to
the indicated groups. C, BV-2 cells were treated with different doses of LPS for 6 h. Upper panel, immunoblots with anti-HO-1 antibody; middle panel,
immunoblots with anti-IBA1 antibody as a control for microglial activation after LPS exposure; lower panel, anti--actin as protein load control. D,
quantification of immunoblots for HO-1 at 6 and 24 h after LPS treatment. One-way ANOVA followed by Newman-Keuls test was used to assess
differences among groups. Asterisks and plus symbols denote significant differences. *, p  0.05; **, p  0.01; ***, p  0.001 comparing the indicated
groups. E, BV-2 cells were treated with different doses of LPS for 24 h. Upper panel, immunoblots with anti-HO-1 antibody; middle panel, immunoblots
with anti-IBA1 antibody as a control for microglial activation after LPS exposure; lower panel, anti--actin as protein load control. F, quantification of
immunoblots for IBA1 at 6 and 24 h after LPS treatment. The statistical analysis was performed as in D. G–J, qRT-PCR determination of mRNA levels of
Ho-1 (G), Nqo1 (H), Il-1 (I), and Tnf (J) normalized by -actin levels. Student’s t test was used to assess differences between groups. Asterisks denote
statistically significant differences with: *, p  0.05; **, p  0.01; ***, p  0.001.
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FIGURE 2.RAC1activates theARE/HO-1pathway.A, HEK-TLR4-MD2/CD14 cellswere treatedwith 1g/ml LPS for 6 and 24h.Upper panel, immunoblotswith
anti-HO-1 antibody; lower panel, anti--actin as protein load control. B, quantification of immunoblots for HO-1 at 6 and 24 h after LPS treatment. Student’s t
test was used to assess differences between groups. Asterisks denote statistically significant differences with: *, p  0.05; **, p  0.01. C and D, qRT-PCR
determination of mRNA levels of Ho-1 (C) and Tnf (D) normalized by -actin levels. One-way ANOVA followed by Newman-Keuls test was used to assess
differences among groups. Asterisks denote significant differences (**, p  0.01; ***, p  0.001) comparing the basal group to the indicated groups. E, LPS
inducesp65andNRF2nuclear translocation.HEK-TLR4-MD2/CD14cellswere treatedwith1g/ml for 15, 30, 60, 120, and180min, and subcellular fractionation
was performed. Upper panels, immunoblots with anti-p65 or NRF2 antibodies; middle panel, immunoblots with GAPDH antibody as a control for cytosolic
protein load; lower panel, anti-laminB (B) as a control for nuclear protein load. F andG, quantificationof immunoblots for p65 (F) orNRF2 (G) after LPS treatment.
One-way ANOVA followed by Newman-Keuls test was used to assess differences among groups. Asterisks and plus denote significant differences: *, p 0.05;
**, p 0.01; ***, p 0.001 comparing the indicated groups. H, HEK-TLR4-MD2/CD14 cells were treated with LPS (1 g/ml) for 5, 10, 20, and 40 min, and cell
lysateswere used to analyze active RAC1 by an active-RAC1-specific antibody (see “Experimental Procedures”). Immunoblots: upper panel, active RAC1;middle
panel, total RAC1; lower panel, GAPDH as protein load control. I, quantification of immunoblots from two independent experiments for active RAC1 and total
RAC1. One-way ANOVA followed byNewman-Keuls test was used to assess differences among groups. Asterisks denote significant differences (**p 0.01; ***,
p 0.001) comparing the basal group to the indicated groups. J, HEK293T cells were transfected with different concentrations of the expression vector for
AU5-tagged RAC1Q61L. Upper panel, HO-1; middle panel, AU5; lower panel, anti-GAPDH as protein loading control. K, quantification of immunoblots for HO-1.
The statistical analysis was performed as in I. L and M, HEK293T cells were transfected with the HO1–15-LUC or ARE-LUC and TK-Renilla control vectors, with
different amounts of RAC1Q61L vector. One-way ANOVA followed by Newman-Keuls test was used to assess differences among groups. Asterisks denote
significant differences (*, p 0.05; **, p 0.01; ***, p 0.001).
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activated kinase 1 (Fig. 1A). We found that LPS (500 ng/ml)
increased the levels of active RAC1 within 5 min and lasted for
at least 40 min (Fig. 1B), indicating that RAC1 is implicated in
LPS signaling. Moreover, LPS induced the expression of the
antioxidant enzymeHO-1 in a dose-dependent fashion after 6 h
(Fig. 1,C andD) andmoremarkedly after 24 h (Fig. 1, E andD).
To control that LPS was inducing an inflammatory response in
BV-2microglial cells, we determined the protein levels of IBA1,
which is expressed in microglia and is up-regulated during the
activation of these cells. LPS induced a dose-dependent and
time-dependent increase of IBA1protein levels (Fig. 1,C,E, and
F), which correlated with the induction of HO-1.We also mea-
sured messenger RNA (mRNA) levels by qRT-PCR of two
NRF2-regulated genes coding HO-1 and NAD(P)H dehydro-
genase, quinone 1(NQO1) and two proinflammatory cytokines,
IL-1 and TNF (Fig. 1, G–J, respectively) and found that treat-
ment with LPS for 24 h increased the mRNA expression of
NRF2-regulated genes and proinflammatory cytokines. These
results indicate that RAC1 is activated very shortly after LPS
stimulation leading to long term transcriptional modifications
that include increased expression of HO-1.
RAC1 Induces theARE/HO-1Axis—LPS stimulation ofHEK-
TLR4-MD2/CD14 cells (humanHEK 293T cells are completely
unresponsive to LPS but acquire high LPS sensitivity after tran-
sient transfection with CD14, TLR4, and MD-2) induced the
expression of protein and mRNA levels of HO-1 (Fig. 2, A–C)
after 6 and 24 h. Increased TNF mRNA levels confirmed the
induction of inflammation due to LPS treatment (Fig. 2D).
FIGURE3.RAC1 inducesNRF2signalingpathway.A, RAC1 inducesNRF2expression in adose-dependentmanner. Cellswere transfectedwithdifferentdoses
of RAC1Q61L and a constant amount of V5-tagged NRF2 or NRF2ETGE-mutant plasmids. Upper panels, immunoblots with anti-AU5 antibody; middle panel,
immunoblots with anti-V5; lower panel, anti-GAPDH as protein load control. B, quantification of immunoblots for NRF2-WT-V5 and NRF2-ETGE-V5. One-way
ANOVA followed by Newman-Keuls test was used to assess differences among groups as previously. C, RAC1 induces NRF2 nuclear translocation. Cells were
co-transfected with or without RAC1Q61L and a constant dose of NRF2ETGE-V5 plasmid, and subcellular fractionation was performed. Upper panels, immuno-
blots with anti-AU5 or V5 antibodies; middle panel, immunoblots with GAPDH antibody as a control for cytosolic protein load; lower panel, anti-lamin B as a
control for nuclear protein load. D, RAC1 requires NRF2 to activate the HO-1 promoter. HEK293T cells were co-transfected with RAC1Q61L expression vector,
pHO1–15-LUC, Renilla control vectors, and either empty vector or dominant negative NRF2, (DN)-NRF2, expression vector. E, RAC1 uses the transactivating
activity of NRF2 to induce AREs. Cells were co-transfected with Gal4-LUC (or pGL3-basic as a control) and either empty vector of expression vectors for
Gal4NRF2 and RAC1 as indicated. Luciferase experiments were performed at least three times using three-four samples per group. The values in graphs
correspond to themean S.E. Student’s t test was used to assess differences between groups or one-way ANOVA followed by a Newman-Keuls post-test (C).
Asterisks denote statistically significant differences with: *, p 0.05; **, p 0.01; ***, p 0.001.
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Besides, LPS induced nuclear translocation of p65 (Fig. 2, E and
F) and NRF2 (Fig. 2, E andG) in a time-dependent manner and
reached amaximumafter 60min. As observed in BV2 cells, LPS
increased the levels of endogenous active RAC1 (Fig. 2,H and I),
indicating that RAC1 activation is an essential effector of LPS
inflammatory process. To analyze in depth the relevance of
RAC1 activation on the NRF2 and NF-B pathways, we trans-
fected HEK293T cells with a constitutively active mutant of
RAC1 (AU5-tagged RAC1Q61L) and analyzed the endogenous
protein levels of HO-1 as a reporter of NRF2 transcriptional
activity. Our results showed that RAC1Q61L increased HO-1
levels in a dose-response manner (Fig. 2, J and K), suggesting a
direct connection between RAC1 activation and expression of
the gene coding HO-1 (HMOX1). To further confirm these
data, we analyzed the induction of two firefly luciferase report-
ers containing either 15 kb of the mouse Hmox1 promoter or
three tandem sequences of the NRF2-dependent antioxidant
response element (ARE-LUC) derived from the Hmox1 pro-
moter.We found a dose-dependent activation of both reporters
(Fig. 2, L andM). These results indicate that NRF2mediates the
RAC1-dependent up-regulation of HO-1 expression.
RAC1Q61L Induces the NRF2/HO-1 Pathway in a Dose-de-
pendent Manner—To determine if RAC1Q61L leads to an
increase in NRF2 protein levels, we co-transfected HEK293T
cells with different concentrations of RAC1Q61L and a constant
concentration of a V5-tagged wild type form of NRF2 (NRF2-
V5) or a stablemutant of NRF2, NRF2ETGE-V5, that lacks four
residues (ETGE) essential for recognition by the E3 ligase com-
plex Cul3/Keap1. The results indicated that RAC1Q61L pro-
duced a dose-dependent accumulation of both wild type
NRF2-V5 and mutant NRF2ETGE-V5 (Fig. 3, A and B). More-
over, we observed by subcellular fractionation that the overex-
pression of RAC1Q61L induced a very strong increase in NRF2
protein levels in both cytosol and nucleus (Fig. 3C).
Moreover, the implication of NRF2 in RAC1-induced HO-1
expression was analyzed with two different strategies. First,
HEK293T cells were co-transfected with the expression vector
for RAC1Q61L, a dominant-negative mutant of NRF2 (DN-
NRF2) lacking the transcriptional activation domain and the
luciferase reporter HO-1-LUC. We observed that DN-NRF2
abolished the RAC1Q61L-mediated induction of HO-1-LUC
reporter (Fig. 3D). Second, we used a one-hybrid assay to study
the transactivating activity of NRF2 in the presence of
RAC1Q61L. The assay consisted of the use of an expression vec-
tor for a fusion protein containing the DNA binding domain of
the yeast transcription factor Gal4 and NRF2 (Gal4-NRF2).
HEK293T cells were co-transfected with RAC1Q61L, Gal4-
NRF2, and the Gal4-LUC reporter plasmid as indicated in Fig.
3E. After 16 h, cells co-transfected with RAC1Q61L and Gal4-
NRF2 exhibited a very strong increase in luciferase activity
compared with that of cells co-transfected with Gal4-LUC and
empty vector. Interestingly, RAC1Q61L highly increased the
transactivating activity of NRF2 compared with NRF2 alone
(Fig. 3E), indicating that RAC1Q61L activates NRF2 by targeting
its transactivation domain. Taken together, all these data
showed that active RAC1 led to accumulation of NRF2, result-
ing in increased ARE gene expression.
NRF2 Modulates RAC1-dependent Activation of the NF-B
Pathway—Considering that RAC1 may participate in produc-
tion of NADPH oxidase-dependent ROS, we further analyzed
the relative production of ROS by RAC1Q61L overexpression in
HEK293T cells by using a dichlorofluorescein probe that emits
green fluorescence in the oxidized form. Although we used dif-
ferent amounts of transfected RAC1Q61L, we only observed a
slight increase in ROS levels in comparison with the effect of
H2O2, used as positive control (Fig. 4A). These results were in
concordance with results obtained with the antioxidant tripep-
tide GSH, which did not have any significant influence in the
activation of the NRF2/HO-1 axis (data not shown), indicating
that the effect of RAC1 on the NRF2 axis may not be mediated
by ROS formation.
We further examined if RAC1Q61L could activate NF-B by
using a luciferase reporter carrying a promoter sequence
(453/80) (HIV-LUC) (27), and we found that RAC1Q61L
activated NF-B in a dose-dependent fashion (Fig. 4B). Addi-
tionally, when we co-transfected different doses of RAC1Q61L
with a constant concentration of p65 and p50 isoforms of
NF-B, we observed an exacerbated effect of RAC1 on the
NF-B transcriptional activity (Fig. 4B). These data indicate
that RAC1 can induce the NF-B responsive element and that
this effect is more potent when both p65 and p50 are increased.
Our data indicate that RAC1 induces the anti-oxidantNRF2/
HO-1 pathway and, on the other hand, that it increases NF-B
activity. To gain further insight into this paradox, we analyzed
the cross-talk betweenNF-B andNRF2 and the implication of
RAC1 in this process. First, we determined if NRF2 couldmod-
ulate NF-B activity by using the HIV-LUC reporter. As
expected, in the presence of a constant dose of p50, we observed
a dose-dependent activation of the reporter by p65 (Fig. 4C).
But, interestingly, co-transfection with the stable form of NRF2
(NRF2ETGE) reduced 	50% of this effect (Fig. 4C), indicating
that NRF2 inhibits NF-B activity. Conversely, when we co-
transfected p50 with increasing doses of p65, we could not
observe an induction of the ARE reporter (Fig. 4D). Addition-
ally, co-transfection of NRF2ETGE with p50/p65 exacerbated
the ARE activity in comparison with that produced by
NRF2ETGE alone (Fig. 4D). Then,we determined the cross-talk
between NRF2 and NF-B by using the HIV-LUC reporter.
FIGURE4.RAC1activatesNF-BpathwaysandNRF2actsasmodulator.A, RAC1overexpression inducesgenerationof intracellular ROS.HEK293Tcellswere
transfectedwith different doses of RAC1Q61L or empty (Ctrl) vectors, and after 16 h cells were incubatedwith 10M 2-7-dihydrodichlorofluorescein diacetate
(H2DCFDA) for 1 h before fluorescencemeasurement. 2mMH2O2 was used as positive control. B, RAC1 induces NF-B pathway. Cells were co-transfectedwith
NF-B-dependent (453/80)HIV-LUC reporter anddifferent concentrations of RAC1Q61L vector in absenceor presenceof p65/p50plasmids.C, NRF2 inhibits
NF-B pathway. Cells were co-transfectedwith HIV-LUC reporter, p50, and increasing amounts of p65 in the absence or presence of NRF2ETGE-V5.D, p65/p50
increased the ARE activity mediated by NRF2. Cells were co-transfected with 3XARE-LUC, p50, and different concentrations of p65 in absence or presence of
NRF2ETGE-V5. E, cells were co-transfected with HIV-LUC reporter, RAC1Q61L, NRF2ETGE-V5, or both in the absence (white bars) or presence (black bars) of
p65/p50. F, cells were co-transfected with HIV-LUC reporter, RAC1Q61L, (DN)-NRF2, or both in the absence (white bars) or presence (black bars) of p65/p50.
One-way ANOVA followed by a Newman-Keuls post-test was used to assess significant differences among groups. Asterisks denote statistically significant
differences with: ***, p 0.001; ##, p 0.01; ###, p 0.001 (respect to their control).
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RAC1Q61L induced NF-B activity (Fig. 4E) as mentioned
before, but when we co-transfected RAC1Q61L with
NRF2ETGE, the activitywas reduced	50%.When p65 and p50
were present, the effects were more pronounced (Fig. 4E). Fur-
thermore, when we co-transfected RAC1Q61L with DN-NRF2,
NF-B transcriptional activity was dramatically increased (Fig.
4F). A similar effect was observed when p65 and p50 were pres-
ent. Taken together, our results suggest that RAC1Q61L induces
inflammation by activating NF-B activity, and p65/p50 coop-
erate with this effect. Moreover, the transcription factor NRF2
modulates this pathway and the absence of NRF2 exacerbates
RAC1-dependent activation of NF-B.
IB Is Implicated in NRF2 and NF-B-p65/p50 Activation by
RAC1Q61L—To investigate the implication of the canonical
pathway of NF-B in the effects mediated by RAC1Q61L, we
used a dominant-negative mutant of IB (IBS32A/S36A) in
which Ser32 and Ser36 residues had been changed to Ala to
block their phosphorylation and, consequently, their degrada-
tion. IBS32A/S36A produced a dose-dependent inhibition of
NF-B by RAC1Q61L (Fig. 5A). This effect was more pro-
nounced in the presence of p65/p50. Then we analyzed the
implication of IBS32A/S36A on ARE activity, and we observed
that the increase of ARE activity induced by RAC1Q61L was inhib-
ited by IBS32A/S36A in a dose-dependentmanner (Fig. 5B). These
data were confirmed by immunoblot analysis. RAC1Q61L expres-
sion increased the protein levels of NRF2ETGE, and co-transfec-
tion of IBS32A/S36A abolished this effect (Fig. 5C), indicating
that RAC1Q61L induced the activation of the NF-B pathway
and consequently the activation of the NRF2/HO-1 axis.
Taken together, those results indicated that IB is neces-
sary for signaling to NF-B and NRF2 through RAC1 activa-
tion. The mechanisms implicated in the cross-talk between
NRF2 and NF-B were analyzed in electrophoretic mobility
shift assays (EMSAs). This method allowed us to establish
whether LPS or RAC1Q61L could promote binding of NRF2 and
p65-NF-B to their respective ARE and NF-B sequences and
to analyze functional interference between them. Nuclear
extracts fromHEK-TLR4-MD2/CD14 cells treated for 1 h with
1 g/ml LPS were incubated with a 32P-labeled, double-
stranded oligonucleotide comprising the ARE or NF-B
sequence (see “Experimental Procedures”). As shown in Fig.
5D, the ARE complex was stronger in the presence of LPS, in
agreement with the accumulation of NRF2 in the nucleus (Fig.
2E). A similar result was observed for the NF-B binding (Fig.
5G). In addition, nuclear extracts from HEK293T cells trans-
fected with RAC1Q61L showed increased complex formation
with the ARE and NF-B sequence (Fig. 5, panels E and F and
panels H and I, respectively). Interestingly, co-transfectionwith
IBS32A/S36A abolished this complex formation for both
probes (Fig. 5, E andH, respectively), confirming the relevance
of IB in signaling to NF-B and NRF2 through RAC1 activa-
tion. Moreover, when RAC1Q61L was co-transfected with DN-
NRF2, the intensity of the ARE complex was decreased in com-
parison toRAC1Q61L alone (Fig. 5F), indicating the loss ofNRF2
in the complex. On the other hand, when RAC1Q61L was co-
transfected with DN-NRF2 and NF-B was analyzed, we
observed several retarded complexes formed with the NF-B
probe, and the intensity of this retarded band was increased
significantly (Fig. 5I), indicating that the absence of NRF2
increased theNF-B complex formation after RAC1 activation.
NF-B-p65 Regulates the NRF2/ARE Pathway—To establish
the relevance of NF-B-p65 in the cross-talk with NRF2, we
used MEFs from p65-knock-out mice (28). Interestingly, the
absence of p65 significantly reduced the mRNA and protein
levels of NRF2 (Fig. 6, A–C). In addition, the mRNA levels of
NRF2-regulated enzymes glutathione peroxidase (Gpx, Fig.
6D), glutathione S-transferase M3 (Gstm3, Fig. 6E), and HO-1
(Fig. 6F) were significantly decreased as well as the protein lev-
els of HO-1 (Fig. 6, G and H).
Finally, we treated these MEFs with SFN, an isothiocyanate
that induces the NRF2 transcriptional signature (29). SFN acti-
vated the transcriptional activity of NRF2 in MEFs from wild
typemice as determined by increasedmRNA and protein levels
of HO-1 (Fig. 6, I–K). In the case of MEFs from p65-knock-out
mice, although SFN was able to induce HO-1 expression, this
effect was greatly attenuated in comparison with wild type
MEFs. These results indicate that the regulation of NRF2 by
NF-B is not related elimination of the KEAP1 constrain and
suggest that the changes in NRF2 levels are due to regulation of
gene expression by NF-B.
NRF2 Modulates the NF-B Pathway at the Post-transla-
tional Level—We used MEFs from NRF2-knock-out mice to
determine the implication of NRF2 on NF-B pathway. The
absence of NRF2 did not modify the mRNA levels of either
p65-NF-B (Fig. 7A) or a p65-related gene Mn-SOD (Fig. 7B).
After 6 h of treatment with 20 ng/ml TNF there was an increase
in both p65-NF-B and MnSOD mRNAs, although there were
not significant changes between genotypes (Fig. 7, A and B),
FIGURE 5. IBmediates the activation of NRF2 andNF-B inducedbyRAC1. A, a dominant-negativemutant of IB (IBS32A/S36A) inhibits RAC1-depen-
dent induction of the NF-B pathway. HEK293T cells were co-transfectedwith HIV-LUC reporter, RAC1Q61L, IBS32A/S36A, or both in the absence (white bars) or
presence (black bars) of p65/p50. B, IB is implicated in the induction of NRF2 by RAC1. Cells were co-transfected with ARE-LUC promoter, RAC1Q61L,
IBS32A/S36A, or both in the absence (white bars) or presence (black bars) of p65/p50. One-way ANOVA followed by a Newman-Keuls post-test was used to
assess significant differences among groups. Asterisks denote statistically significant differences with: *, p 0.05; **, p 0.005; ***, p 0.001; ###, p 0.001
(with respect to their control). C, Western blot analysis of cells co-transfected with RAC1Q61L, IBS32A/S36A, and NRF2ETGE-V5 and their respective controls.
Upper panel, immunoblot with anti-V5 antibody;middle panel, immunoblot with anti-AU5; lower panel, anti-GAPDH as protein load control. D, EMSA, using a
double-stranded oligonucleotide containing the core ARE sequence and nuclear extracts from HEK-TLR4-MD2/CD14 cells treated with 1 g/ml LPS for 1 h. E,
EMSA, using a double-stranded oligonucleotide containing the core ARE sequence andnuclear extracts fromHEK293T cells expressing RAC1Q61L IBS32A/S36A.
F, EMSA,usingadouble-strandedoligonucleotide containing thecoreARE sequenceandnuclear extracts fromHEK293Tcells expressingRAC1Q61LDN-NRF2.
In all cases the concentration of unlabeled oligonucleotide was 100 in the competition binding between labeled and unlabeled ARE probe. G, EMSA, using
a double-stranded oligonucleotide containing the NF-B binding element and nuclear extracts from HEK-TLR4-MD2/CD14 cells treated with 1 g/ml LPS for
1 h. H, EMSA, using a double-stranded oligonucleotide containing the NF-B promoter sequence and nuclear extracts from HEK293T cells expressing
RAC1Q61L IBS32A/S36A. I, EMSA, using a double-stranded oligonucleotide containing the NF-B promoter sequence and nuclear extracts fromHEK293T cells
expressing RAC1Q61L  DN-NRF2. In all cases the concentration of unlabeled oligonucleotide was 100 in the competition binding between labeled and
unlabeled NF-B probe. IkB* stands for IkB S32A/S36A mutations (a mutated plasmid).  indicates that the complete sample is Rac1Q61L  DN-NRF2, for
example.
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indicating that the NRF2 does not modify p65-NF-B gene
expression. However, the absence of NRF2 increased the
amount of p65-NF-B protein (Fig. 7, C and D) and p65-NF-
B-dependent proteins likeMnSOD (Fig. 7,C and E) and XIAP
(Fig. 7, C and F). TNF treatment for 6 h induced the protein
expression of p65-NF-B, MnSOD, and XIAP (Fig. 7, C–F)
without changes between genotypes except for XIAP. We
found that NRF2-deficient MEFs expressed decreased XIAP
levels in comparison to NRF2/-MEFs treated with TNF.
Taken together, these results indicate that there is cross-talk
between NRF2 and NF-B pathways at protein and transacti-
vation levels.
DISCUSSION
Low grade inflammation is present in several degenerative
diseases, and RAC1 is a mediator of inflammatory signals. For
FIGURE 6.NRF2/AREpathway ismodulatedbyp65-NF-B.A and B, NRF2 expression is decreased in p65/MEFs.A, qRT-PCRdetermination ofmRNA levels
ofNrf2normalizedby-actin levels. B, immunoblot analysis of NRF2protein levels, GAPDHwas used as load control.C, quantification of immunoblots for NRF2
protein levels. Decreased levels of phase two enzymes in p65/MEFs. qRT-PCR determination of mRNA levels of Gstm3 (D), Gpx (E), and Ho-1 (F) normalized
by -actin levels. Dpx, glutathione peroxidase. G, immunoblot analysis of HO-1 protein levels, GAPDH was used as load control. H, quantification of immuno-
blots for HO-1 protein levels. Student’s t test was used to assess differences between groups. Asterisks denote statistically significant differences with: *, p
0.05; **, p 0.01; ***, p 0.001. p65/ and p65/MEFwere incubated in a serum-freemediumwith 14Mof SFN for 6 h. I, qRT-PCR determination ofmRNA
levels of Ho-1 normalized by -actin levels. J, immunoblot analysis of HO-1 protein levels; GAPDH was used as load control. K, quantification of immunoblots
for HO-1 protein levels. Two-way ANOVA followed by a Bonferroni post-test was used to assess significant differences among groups. Asterisks denote
statistically significant differences with: *, p 0.05; ***, p 0.001.
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instance, in amyotrophic lateral sclerosis (ALS), SOD1 muta-
tions disrupt redox-sensitive RAC1 regulation of NADPH oxi-
dase (30). In Fragile X syndrome, the most common hereditary
form ofmental retardation, lack of Fragile Xmental retardation
protein (FMRP) induced an overactivation of RAC1 in the
mouse brain, indicating that regulation of RAC1may provide a
functional link amongdeficient neuronalmorphology, aberrant
synaptic plasticity, and cognition impairment in this disease
(31). Interestingly, in Alzheimer disease it has been found that
RAC1 inhibition targets amyloid precursor protein processing
by -secretase and decreases A production in vitro and in vivo
(32). But RAC1 is not only involved in neurodegenerative dis-
orders. Mutations in the RAC1 gene are associated with higher
risk of inflammatory bowel disease (33). Intriguingly, loss of
RAC1 expression results in protection from colitis (34). We
hypothesize that RAC1 may be an essential mediator in several
inflammation-related disorders through the activation ofNRF2
and NF-B pathways.
Taking RAC1 as a crucial mediator in inflammatory pro-
cesses, our study focused on the modulation by this protein of
two transcription factors, NRF2 andNF-B, which are themas-
ter regulators of anti-oxidant (HO-1, NADP(H) quinone oxi-
doreductase (NQO1), and others) and proinflammatory (IL-1,
TNF, and others) responses, respectively. We describe that
RAC1 induces the expression of the anti-oxidant enzymeHO-1
through the NRF2/ARE axis. Interestingly, RAC1 induces the
nuclear translocation of NRF2 and increases its transactivating
activity, suggesting that RAC1 could modulate the NRF2/ARE
pathway under pathophysiological conditions. In concordance
with these results, it has been described that auranofin, a glod
(I)-containing anti-rheumatic drug, possesses anti-inflamma-
tory properties due to HO-1 induction and NF-B inhibition,
and this correlates with the activation of RAC1 (35). Also,
15-deoxy-D12,14-prostaglandin J2, which is an immunoregu-
latory lipid metabolite derived from prostaglandin D2 dehydra-
tion, exerts anti-inflammatory activity through the RAC1-
FIGURE 7.NRF2 deficiency increased p65-NF-B protein levels. A and B, qRT-PCR determination of mRNA levels of p65-NF-B (A) orMnSOD (B) normalized
by -actin levels in NRF2/ and NRF2/MEFs at basal conditions and after 6 h of TNF- (20 ng/ml) treatment. C, immunoblots analysis of p65, MnSOD, and
XIAP protein levels GAPDH was used as load control in NRF2/ and NRF2/ MEFs at basal conditions and after 6 h TNF- (20 ng/ml) treatment. D--F,
quantificationof immunoblots forp65-NF-B (D),MnSOD (E), andXIAP (F) protein levels. Two-wayANOVA followedbyaBonferroni post-testwasused toassess
significant differences among groups. Asterisks denote statistically significant differences with: *, p 0.05; **, p 0.01; ***, p 0.001.
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NADPH oxidase-ROS-p38 signaling and up-regulation of
HO-1 inmurinemacrophages treatedwith LPS (36). This path-
way differs from ours because, although RAC1Q61L induced a
slight increase in ROS production (Fig. 4A), treatment with the
antioxidant GSH did not reverse HO-1 induction, indicating
that other pathways, independent of NADPH oxidase, could be
involved as well.
Constitutively active RAC1 induces the accumulation and
nuclear translocation of NRF2 (Fig. 3, A and C, respectively) in
a KEAP1-independent manner because RAC1 was able to
induce NRF2ETGE-V5, which lacks four residues (ETGE)
essential for recognition by this E3 ligase adapter. It seems that
NRF2 induction through RAC1 is KEAP1-independent in our
model even though KEAP1 overexpression inhibits RAC1 on
the formation of E-cadherin-mediated cell-cell adhesion (37). It
has been widely reported that RAC1 participates in several sig-
naling kinase pathways, including MAPKs and PI3K (38, 39).
Our group has reported a KEAP-independent regulation of
NRF2 that relies on signaling kinases PI3K/AKT (40). There-
fore, as shown in Fig. 8A, we suggest that through activation of
the PI3K/AKT axis, RAC1 leads to NRF2 transcriptional
activity.
FIGURE 8. Implication of RAC1 in NF-B and NRF2 transcriptional activities mediated by IB. A, RAC1 activation induces NF-B and NRF2 transcription
factors through IB implicated in different processes like oxidative stress, inflammation, or phagocytosis. But there are other pathways that could be
implicated in these activation like PI3K and MAPK or the generation of ROS generated by NAPDH oxidase. B, in the absence of p65 there is a suboptimal
expression of the Nrf2 and ARE-regulated genes, which are unable to regulate properly inflammation. The Nrf2 gene has a NF-B binding site at the270 bp
from the TSS to which p65/p50 heterodimer is recruited (11). C, in the absence of NRF2 there is no propermodulation of redox homeostasis, which could lead
to IB degradation, and therefore, we observed increased p65 protein levels, which could induce inflammation.
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The emerging roles of RAC1 in inflammation led us to ana-
lyze the cross-talk between RAC1, NRF2, and NF-B. Our
results showed that activated RAC1 can induce the NF-B
pathway and cooperate with p65 and p50 in a dose-response
manner (Fig. 4B) and that NRF2 acts as a modulator in this
scenario. NRF2 overexpression inhibits RAC1-dependent acti-
vation of the NF-B pathway and the absence of NRF2 due to
overexpression of the DN-NRF2, exacerbated the activation of
NF-B-dependent inflammatory markers (Fig. 4, E and F,
respectively). Therefore, our data indicate that RAC1 through
IB (Fig. 5, A–C) induces NF-B, which in turn modulates
NRF2. ThenNRF2 inhibitsNF-B as a regulatory feedback loop
(Fig. 8A). Regarding this, we had previously observed that -sy-
nuclein induced both the NF-B proinflammatory and NRF2
anti-inflammatory responses but with different kinetics in BV2
microglial cells. We suggested that NF-B activation is an early
and direct event of -synuclein signaling, whereas Nrf2 is a
secondary event that participates in a later negative loop of
NF-B regulation (14). Moreover, we propose that these new
results may explain our previous observation of exacerbated
inflammatory response to LPS (12) or overexpression of -
synuclein (14) or TAU (41) in NRF2-deficient mice. In the
absence of NRF2, NF-B lacks a controller to switch off the
inflammatory signal. Consistently, in animals treated with sul-
foraphane, an NRF2 inducer, the production of inflammatory
markers in response to LPS was attenuated. These results are
sustained by the presence of a NF-B binding site in the Nrf2
gene (42) (Fig. 8B) and by the fact that IK- (IB kinase)
contains an ETGE motif that enables it to bind to KEAP1 (43,
44). Also, NRF2 deficiency results in increased ROS levels,
which induce IB phosphorylation and subsequent degrada-
tion, increasing p65-NF-B levels and NF-B proinflammatory
processes (Fig. 8C). Therefore, RAC1 has an essential rolemod-
ulating NRF2 and NF-B pathways.
One of the hallmarks of RAC1 is its pleiotropic effects, regu-
lating different cellular pathways. RAC1 participates in -actin
reorganization, and thus it has been implicated in inflammatory
phagocytosis (45, 46). On the other hand, recent evidences
showed that NRF2 is also implicated in phagocytosis. We and
others have reported lower phagocytic index in microglial cells
and macrophages from NRF2-deficient mice (14, 47),
although the mechanism is unknown. Interestingly, sul-
foraphane is able to stimulate phagocytosis, indicating again
a relevant role of NRF2 in this process (47). We hypothesize
that the activation of RAC1 promotes -actin-dependent
cytoskeletal changes as well as oxidative processes, which
lead to the induction of NRF2 and finally to phagocytosis.
This mechanism could be highly relevant in neurodegenera-
tive diseases like Alzheimer disease, where RAC1 partici-
pates in microglial phagocytosis of -amyloid (48) and reg-
ulates the transcriptional activity of the amyloid precursor
protein gene (49). Together, our results provide a new cross-
talk mechanism of regulation of inflammatory processes
involving RAC1 and the balance between NRF2 and NF-B
activities, which could be relevant in several pathophysiolog-
ical events related to inflammation.
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